Dr. Whitley talks with Dr. Bobby Azamian, co-founder, president and CEO of Tarsus Pharmaceuticals, about a topic that we haven’t addressed before on the Dry Eye Coach Podcast, which is addressing an unmet need for 25 million Americans: Demodex blepharitis.
Tarsus is developing TP-03, which is a drug that has the potential to be the first FDA approved treatment for Demodex Blepharitis.
Click Here to read the transcript of this podcast.
Dry Eye Coach
Dropping the Mic on Demodex: The Final Word by Dr. Bobby Azamian on Blepharitis
Dr. Whitley talks with Dr. Bobby Azamian, co-founder, president and CEO of Tarsus Pharmaceuticals, about a topic that we haven’t addressed before on the Dry Eye Coach Podcast, which is addressing an unmet need for 25 million Americans: Demodex blepharitis.
Tarsus is developing TP-03, which is a drug that has the potential to be the first FDA approved treatment for Demodex Blepharitis.
